DNAtrix is a privately held, clinical stage, biopharmaceutical company developing oncolytic virus immunotherapies for cancer. We leverage the significant advantages of oncolytic viruses to develop safe and effective therapies for difficult cancers, including glioblastoma and other high grade tumors. Based on the natural ability of certain viruses to trigger a robust antitumor immune response, we are building a pipeline of virus-based drugs for use as monotherapy or in combination with checkpoint inhibitors and other immuno-oncology drugs. DNAtrix’s lead product, DNX-2401, is a conditionally replicative oncolytic adenovirus being evaluated in clinical trials for recurrent glioblastoma, a brain cancer for which there is neither a cure nor adequate treatment. DNX-2401 initiates a chain reaction of tumor cell killing by selectively replicating within glioblastoma cells (but not normal cells), causing tumor destruction and further spread of the oncolytic virus to adjacent tumor cells. This process then triggers an immune response directed against the tumor. DNX-2401 has been well tolerated in patients with recurrent glioblastoma and survival has been prolonged compared to other therapies. In collaboration with Merck, we are currently enrolling a multi-centered Phase 2 study evaluating the efficacy and safety of DNX-2401 in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD- 1 therapy, in patients with recurrent glioblastoma.
Session ID: 26614